# US 2024/0199744 A1 · Therapeutic methods using constrained conditionally activated binding proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199744 A1
- Document ID: US20240199744A1
- Status: Published application
- Kind: A1
- Application number: 18/285,714
- Filed: 2022-04-06
- Published: 2024-06-20
- Earliest claimed: 2021-04-06
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Chad Michael May; Robert B. DuBridge; Maia Vinogradova; Anand Panchal
- Web page: https://patentgrep.com/patent/US20240199744A1

## CPC

- C07K 16/18: against material from animals or humans
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/30: from tumour cells
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/62: comprising only variable region components
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K 2319/50: containing protease site
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

## Claims

### Claim 1

A method for treating cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a polypeptide comprising, from N- to C-terminus:
a) a first single domain antigen binding domain (sdABD) that binds to a first human tumor target antigen (TTA);
b) a first domain linker;
c) a constrained Fv domain comprising:
i) a first variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3;
ii) a constrained non-cleavable linker (CNCL); and
iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3, wherein the CNCL is positioned between the first variable heavy domain and the first variable light domain and prevents the first variable heavy domain and the first variable light domain from interacting to form an active Fv capable of binding CD3;
d) a second domain linker;
e) a second sdABD that binds to a second human TTA;
f) a cleavable linker (CL);
g) a pseudo Fv domain comprising:
i) a first pseudo variable light domain;
ii) a non-cleavable linker (NCL); and
iii) a first pseudo variable heavy domain:
h) a third domain linker; and
i) a third sdABD that binds to human serum albumin;
wherein:
the first variable heavy domain and the first variable light domain are capable of binding human CD3 but said constrained Fv domain does not bind CD3; and
the polypeptide does not bind CD3 when the CL is intact.

### Claim 2

A method for treating cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a polypeptide comprising, from N- to C-terminus:
a) a first single domain antigen binding domain (sdABD) that binds to human serum albumin;
b) a first domain linker;
c) a pseudo Fv domain comprising:
i) a first pseudo variable light domain;
ii) a non-cleavable linker (NCL); and
iii) a first pseudo variable heavy domain;
d) a cleavable linker (CL);
e) a second sdABD that binds to a first human tumor target antigen (TTA);
f) a second domain linker;
g) a constrained Fv domain comprising:
i) a second variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3;
ii) a constrained non-cleavable linker (CNCL); and
iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3, wherein the CNCL is positioned between the first variable heavy domain and the first variable light domain and prevents the first variable heavy domain and the first variable light domain from interacting to form an active Fv capable of binding CD3;
h) a third domain linker;
i) a third second sdABD that binds to a second human TTA:
wherein:
the first variable heavy domain and the first variable light domain are capable of binding human CD3 but said constrained Fv domain does not bind CD3; and
the polypeptide does not bind CD3 when the CL is intact.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the cancer is a solid tumor.

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1-3, wherein the cancer is an unresectable cancer.

### Claim 5 (depends on 1, 2, 3, 4)

The method according to any one of claims 1-4, wherein the cancer is a metastatic cancer.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1-5, wherein the cancer is a carcinoma of the head and neck.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cancer is a squamous cell carcinoma.

### Claim 8 (depends on 7)

The method of claim 7, wherein the squamous cell carcinoma progressed during or following combination therapy with a platinum-based chemotherapeutic agent and a checkpoint inhibitor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the checkpoint inhibitor is an anti-PD1 antibody or antigen binding fragment thereof.

### Claim 10 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1-5, wherein the cancer is a lung cancer.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cancer is a non-small-cell lung cancer.

### Claim 12 (depends on 11)

The method of claim 11, wherein the non-small-cell lung cancer progressed during or following combination therapy with a platinum-based chemotherapeutic agent and a checkpoint inhibitor.

### Claim 13 (depends on 12)

The method of claim 12, wherein the checkpoint inhibitor is an anti-PD1 antibody or antigen binding fragment thereof.

### Claim 14 (depends on 10, 11, 12, 13)

The method according to any one of claims 10-13, wherein the non-small-cell lung cancer carries an EGFR mutation.

### Claim 15 (depends on 14)

The method of claim 14, wherein the cancer progressed during or following therapy with an EGFR targeted therapy.

### Claim 16 (depends on 10, 11, 12, 13, 14, 15)

The method according to any one of claims 10-15, wherein the non-small-cell lung cancer carries an ALK rearrangement.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer progressed during or following therapy with an ALK targeted therapy.

### Claim 18 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1-5, wherein the cancer is a colorectal cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the colorectal cancer progressed during or following combination therapy with a platinum-based chemotherapeutic agent and a checkpoint inhibitor.

### Claim 20 (depends on 19)

The method of claim 19, wherein the checkpoint inhibitor is an anti-PD1 antibody or antigen binding fragment thereof.

### Claim 21 (depends on 18, 19, 20)

The method according to any one of claims 18-20, wherein the colorectal cancer does not carry a K-Ras mutation.

### Claim 22 (depends on 21)

The method of claim 21, wherein the colorectal cancer progressed during or following a combination of irinotecan or oxaliplatin based chemotherapy and the patient has relapsed or is refractory to at least one prior systemic therapy that included an EGFR targeted therapy.

### Claim 23 (depends on 21)

The method of claim 21, wherein:
the patient is ineligible for both irinotecan and oxaliplatin based chemotherapy; and
the patient has relapsed or is refractory to at least one prior systemic therapy that included an EGFR targeted therapy.

### Claim 24 (depends on 18, 19, 20)

The method according to any one of claims 18-20, wherein the colorectal cancer carries a K-Ras mutation.

### Claim 25 (depends on 24)

The method of claim 24, wherein the colorectal cancer progressed during or following irinotecan or oxaliplatin based chemotherapy.

### Claim 26 (depends on 24)

The method of claim 24, wherein the patient is ineligible for both irinotecan and oxaliplatin based chemotherapy.

### Claim 27 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1-5, wherein the cancer is a prostate cancer.

### Claim 28 (depends on 27)

The method of claim 27, wherein the prostate cancer progressed during or following platinum-based chemotherapy.

### Claim 29 (depends on 27, 28)

The method of claim 27 or 28, wherein the prostate cancer progressed during or following an anti-PDx therapy.

### Claim 30 (depends on 27, 28, 29)

The method according to any one of claims 27-29, wherein the efficacy of the treatment is assessed by measuring the level of prostate-specific antigen (PSA) and/or prostate-specific membrane antigen (PSMA) via a blood test and/or a positron emission tomography (PET) scan.

### Claim 31 (depends on 28)

The method of claim 28, wherein a reduction in the PSA or PSMA levels of the patient of at least a threshold amount following a treatment regimen comprising the administration of the polypeptide spanning at least a minimal time threshold indicates successful therapy.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the patient has an ECOG performance status of at least grade 1.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1-32, wherein the patient has measurable disease as per RECIST v1.1 criteria and documented by CT and/or MRI.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-33, wherein the patient has previously treated symptomatic central nervous system metastases.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the patient does not have concurrent leptomeningeal disease.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein said first and second TTA is the same.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein said first and second TTA are different.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method according to any of claims 1-37, wherein said first and second human TTA are selected from EGFR and B7H3.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method according to any of claims 1-37, wherein said first and second sdABD-TTAs are selected from the group consisting of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:29; SEQ ID NO:33; SEQ ID NO:37 and SEQ ID NO:41.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method according to any of claims 1-39, wherein said half-life extension domain has SEQ ID NO:45.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method according to any of claims 1-40, wherein said cleavable linker is cleaved by a human protease selected from the group consisting of MMP2, MMP9, Meprin A, Meprin B, Cathepsin S, Cathepsin K, Cathespin L, GranzymeB, uPA, Kallekriein7, matriptase and thrombin.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:143 (Pro140), SEQ ID NO:144 (Pro140b), SEQ ID NO:185 (Pro141), SEQ ID NO: 199 (Pro176), SEQ ID NO:208 (Pro188), SEQ ID NO:200 (Pro178), SEQ ID NO:201 (Pro179), SEQ ID NO:202 (Pro180), SEQ ID NO:203 (Pro181), SEQ ID NO:204 (Pro182), SEQ ID NO:205 (Pro183), SEQ ID NO:206 (Pro184), SEQ ID NO:207 (Pro185), SEQ ID NO:145 (Pro186), SEQ ID NO:146 (Pro187), SEQ ID NO:189 (Pro189), SEQ ID NO:2 (Pro190), SEQ ID NO:191 (Pro191), SEQ ID NO:212 (Pro192), SEQ ID NO:214 (Pro195), SEQ ID NO:215 (Pro196), SEQ ID NO:216 (Pro197), SEQ ID NO:217 (Pro198), SEQ ID NO:165 (SEQ ID NO:221), SEQ ID NO: 166 (Pro222), SEQ ID NO:167 (Pro223), SEQ ID NO:168 (Pro224), SEQ ID NO:149 (Pro233), SEQ ID NO:226 (Pro247), SEQ ID NO:227 (Pro248), SEQ ID NO:228 (Pro249), SEQ ID NO:299 (Pro250), SEQ ID NO:230 (Pro251), SEQ ID NO:231 (Pro252), SEQ ID NO:232 (Pro253), SEQ ID NO:153 (Pro246), SEQ ID NO:169 (Pro254), SEQ ID NO:170 (Pro255), SEQ ID NO:154 (Pro256), SEQ ID NO:233 (Pro261), SEQ ID NO:171 (Pro262), SEQ ID NO:234 (Pro294), SEQ ID NO:250 (Pro345), SEQ ID NO:259 (Pro375), SEQ ID NO:260 (Pro376), SEQ ID NO:157 (Pro393), SEQ ID NO:158 (Pro394), SEQ ID NO:159 (Pro395), SEQ ID NO: 160 (Pro396), SEQ ID NO:263 (Pro412), SEQ ID NO:264 (Pro413), SEQ ID NO:265 (Pro414), SEQ ID NO:265 (Pro415), SEQ ID NO:266 (Pro416), SEQ ID NO:267 (Pro417), SEQ ID NO:269 (Pro418), SEQ ID NO:272 (Pro429), SEQ ID NO:162 (Pro430), and SEQ ID NO:163 (Pro431).

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:145 (Pro186).

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:149 (Pro233).

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:153 (Pro246).

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:169 (Pro254).

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:232 (Pro253).

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:234 (Pro294).

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:147 (Pro225), SEQ ID NO:148 (Pro226), SEQ ID NO:173 (Pro359), SEQ ID NO:257 (Pro373), SEQ ID NO:258 (Pro374), SEQ ID NO:181 (Pro479), SEQ ID NO:182 (Pro480), and SEQ ID NO:183 (Pro495).

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:147 (Pro225).

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:148 (Pro226).

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:173 (Pro359).

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:257 (Pro373).

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:258 (Pro374).

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 181 (Pro479).

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:182 (Pro480).

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method according to any of claims 1-35, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:183 (Pro495).

### Claim 58

A method for treating a colorectal cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a polypeptide comprising, from N- to C-terminus:
a) a first single domain antigen binding domain (sdABD) that binds to a first human tumor target antigen (TTA);
b) a first domain linker;
c) a constrained Fv domain comprising:
i) a first variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3;
ii) a constrained non-cleavable linker (CNCL); and
iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3, wherein the CNCL is positioned between the first variable heavy domain and the first variable light domain and prevents the first variable heavy domain and the first variable light domain from interacting to form an active Fv capable of binding CD3;
d) a second domain linker;
e) a second sdABD that binds to a second human TTA;
f) a cleavable linker (CL);
g) a pseudo Fv domain comprising:
i) a first pseudo variable light domain;
ii) a non-cleavable linker (NCL); and
iii) a first pseudo variable heavy domain;
h) a third domain linker; and
i) a third sdABD that binds to human serum albumin;
wherein:
at least one of the first human TTA and the second human TTA is EGFR;
the first variable heavy domain and the first variable light domain are capable of binding human CD3 but said constrained Fv domain does not bind CD3; and
the polypeptide does not bind CD3 when the CL is intact.

### Claim 59

A method for treating a colorectal cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a polypeptide comprising, from N- to C-terminus:
a) a first single domain antigen binding domain (sdABD) that binds to human serum albumin;
b) a first domain linker;
c) a pseudo Fv domain comprising:
i) a first pseudo variable light domain;
ii) a non-cleavable linker (NCL); and
iii) a first pseudo variable heavy domain;
d) a cleavable linker (CL);
e) a second sdABD that binds to a first human tumor target antigen (TTA);
f) a second domain linker;
g) a constrained Fv domain comprising:
i) a second variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3;
ii) a constrained non-cleavable linker (CNCL); and
iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3, wherein the CNCL is positioned between the first variable heavy domain and the first variable light domain and prevents the first variable heavy domain and the first variable light domain from interacting to form an active Fv capable of binding CD3;
h) a third domain linker;
i) a third second sdABD that binds to a second human TTA;
wherein:
at least one of the first human TTA and the second human TTA is EGFR;
the first variable heavy domain and the first variable light domain are capable of binding human CD3 but said constrained Fv domain does not bind CD3; and
the polypeptide does not bind CD3 when the CL is intact.

### Claim 60 (depends on 58, 59)

The method of claim 58 or 59, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:143 (Pro140), SEQ ID NO:144 (Pro140b), SEQ ID NO:185 (Pro141), SEQ ID NO:199 (Pro176), SEQ ID NO:208 (Pro188), SEQ ID NO:200 (Pro178), SEQ ID NO:201 (Pro179), SEQ ID NO:202 (Pro180), SEQ ID NO:203 (Pro181), SEQ ID NO:204 (Pro182), SEQ ID NO:205 (Pro183), SEQ ID NO:206 (Pro184), SEQ ID NO:207 (Pro185), SEQ ID NO:145 (Pro186), SEQ ID NO:146 (Pro187), SEQ ID NO:189 (Pro189), SEQ ID NO:2 (Pro190), SEQ ID NO:191 (Pro191), SEQ ID NO:212 (Pro192), SEQ ID NO:214 (Pro195), SEQ ID NO:215 (Pro196), SEQ ID NO:216 (Pro197), SEQ ID NO:217 (Pro198), SEQ ID NO:165 (SEQ ID NO:221), SEQ ID NO:166 (Pro222), SEQ ID NO:167 (Pro223), SEQ ID NO:168 (Pro224), SEQ ID NO:149 (Pro233), SEQ ID NO:226 (Pro247), SEQ ID NO:227 (Pro248), SEQ ID NO:228 (Pro249), SEQ ID NO:299 (Pro250), SEQ ID NO:230 (Pro251), SEQ ID NO:231 (Pro252), SEQ ID NO:232 (Pro253), SEQ ID NO:153 (Pro246), SEQ ID NO:169 (Pro254), SEQ ID NO:170 (Pro255), SEQ ID NO:154 (Pro256), SEQ ID NO:233 (Pro261), SEQ ID NO:171 (Pro262), SEQ ID NO:234 (Pro294), SEQ ID NO:250 (Pro345), SEQ ID NO:259 (Pro375), SEQ ID NO:260 (Pro376), SEQ ID NO:157 (Pro393), SEQ ID NO:158 (Pro394), SEQ ID NO: 159 (Pro395), SEQ ID NO:160 (Pro396), SEQ ID NO:263 (Pro412), SEQ ID NO:264 (Pro413), SEQ ID NO:265 (Pro414), SEQ ID NO:265 (Pro415), SEQ ID NO:266 (Pro416), SEQ ID NO:267 (Pro417), SEQ ID NO:269 (Pro418), SEQ ID NO:272 (Pro429), SEQ ID NO:162 (Pro430), and SEQ ID NO:163 (Pro431).

### Claim 61 (depends on 58, 59)

The method of claim 58 or 59, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:145 (Pro186), SEQ ID NO:149 (Pro233), SEQ ID NO:153 (Pro246), SEQ ID NO:169 (Pro254), SEQ ID NO:232 (Pro253), and SEQ ID NO:234 (Pro294).

### Claim 62 (depends on 58, 59)

The method of claim 58 or 59, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:145 (Pro186).

### Claim 63 (depends on 58, 59, 60, 61, 62)

The method according to any one of claims 58-62, wherein the colorectal cancer progressed during or following combination therapy with a platinum-based chemotherapeutic agent and a checkpoint inhibitor.

### Claim 64 (depends on 63)

The method of claim 63, wherein the checkpoint inhibitor is an anti-PD1 antibody or antigen binding fragment thereof.

### Claim 65 (depends on 58, 59, 60, 61, 62, 63, 64)

The method according to any one of claims 58-64, wherein the colorectal cancer does not carry a K-Ras mutation.

### Claim 66 (depends on 65)

The method of claim 65, wherein the colorectal cancer progressed during or following a combination of irinotecan or oxaliplatin based chemotherapy and the patient has relapsed or is refractory to at least one prior systemic therapy that included an EGFR targeted therapy.

### Claim 67 (depends on 65)

The method of claim 65, wherein:
the patient is ineligible for both irinotecan and oxaliplatin based chemotherapy; and
the patient has relapsed or is refractory to at least one prior systemic therapy that included an EGFR targeted therapy.

### Claim 68 (depends on 58, 59, 60, 61, 62, 63, 64)

The method according to any one of claims 58-64, wherein the colorectal cancer carries a K-Ras mutation.

### Claim 69 (depends on 68)

The method of claim 68, wherein the colorectal cancer progressed during or following irinotecan or oxaliplatin based chemotherapy.

### Claim 70 (depends on 68)

The method of claim 68, wherein the patient is ineligible for both irinotecan and oxaliplatin based chemotherapy.

### Claim 71

A method for treating a head and neck squamous cell carcinoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a polypeptide comprising, from N- to C-terminus:
a) a first single domain antigen binding domain (sdABD) that binds to a first human tumor target antigen (TTA);
b) a first domain linker;
c) a constrained Fv domain comprising:
i) a first variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3;
ii) a constrained non-cleavable linker (CNCL); and
iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3, wherein the CNCL is positioned between the first variable heavy domain and the first variable light domain and prevents the first variable heavy domain and the first variable light domain from interacting to form an active Fv capable of binding CD3;
d) a second domain linker;
e) a second sdABD that binds to a second human TTA;
f) a cleavable linker (CL);
g) a pseudo Fv domain comprising:
i) a first pseudo variable light domain;
ii) a non-cleavable linker (NCL); and
iii) a first pseudo variable heavy domain;
h) a third domain linker; and
i) a third sdABD that binds to human serum albumin;
wherein:
at least one of the first human TTA and the second human TTA is B7H3;
the first variable heavy domain and the first variable light domain are capable of binding human CD3 but said constrained Fv domain does not bind CD3; and
the polypeptide does not bind CD3 when the CL is intact.

### Claim 72

A method for treating a head and neck squamous cell carcinoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a polypeptide comprising, from N- to C-terminus:
a) a first single domain antigen binding domain (sdABD) that binds to human serum albumin;
b) a first domain linker;
c) a pseudo Fv domain comprising:
i) a first pseudo variable light domain;
ii) a non-cleavable linker (NCL); and
iii) a first pseudo variable heavy domain;
d) a cleavable linker (CL);
e) a second sdABD that binds to a first human tumor target antigen (TTA);
f) a second domain linker;
g) a constrained Fv domain comprising:
i) a second variable heavy domain comprising a vhCDR1, vhCDR2 and vhCDR3;
ii) a constrained non-cleavable linker (CNCL); and
iii) a first variable light domain comprising vlCDR1, vlCDR2 and vlCDR3, wherein the CNCL is positioned between the first variable heavy domain and the first variable light domain and prevents the first variable heavy domain and the first variable light domain from interacting to form an active Fv capable of binding CD3;
h) a third domain linker;
i) a third second sdABD that binds to a second human TTA;
wherein:
at least one of the first human TTA and the second human TTA is B7H3;
the first variable heavy domain and the first variable light domain are capable of binding human CD3 but said constrained Fv domain does not bind CD3; and
the polypeptide does not bind CD3 when the CL is intact.

### Claim 73 (depends on 71, 72)

The method of claim 71 or 72, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:147 (Pro225), SEQ ID NO:148 (Pro226), SEQ ID NO:173 (Pro359), SEQ ID NO:257 (Pro373), SEQ ID NO:258 (Pro374), SEQ ID NO:181 (Pro479), SEQ ID NO:182 (Pro480), and SEQ ID NO:183 (Pro495).

### Claim 74 (depends on 71, 72)

The method of claim 71 or 72, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:147 (Pro225).

### Claim 75 (depends on 71, 72, 73, 74)

The method according to any one of claims 71-74, wherein the squamous cell carcinoma progressed during or following combination therapy with a platinum-based chemotherapeutic agent and a checkpoint inhibitor.

### Claim 76 (depends on 75)

The method of claim 75, wherein the checkpoint inhibitor is an anti-PD1 antibody or antigen binding fragment thereof.
